07 April – Clinical aspects of targeted treatments for lung cancer

Monday 07 April 2014, Royal Marsden Hospital London

1-day course: Clinical Aspects of Targeted Treatments for Lung Cancer

Level: Advanced

Description: This course summarises our current understanding of the molecular pathology and classification of small cell and non-small cell lung cancer. It also explains the scientific rationale behind targeted treatments in use and in development for these diseases, such as EGFR inhibitors (Iressa, Tarceva, Erbitux), ALK inhibitors (crizotinib), angiogenesis inhibitors (Avastin), MET/HGF inhibitors and FGF inhibitors. In the afternoon there will be opportunity to discuss the management of treatment side effects and work through patient case studies.

Audience: Ideal for doctors, research nurses and other oncology staff caring for patients with lung cancer.

To book, contact: henry.coleman@rmh.nhs.uk Tel. 020 7808 2922


Introduction to lung cancer: a disease of many layers
  • DNA damage: causes, types and consequences
  • Epigenetics – the chicken or the egg?
  • Cancer cells and their microenvironment – cellular diversity and cell-cell communication pathways
  • Cancer stem cells and the EMT
  • Genetic instability and intra-tumoural heterogeneity: the new enemies
Introducing non-small cell lung cancer
  • Mechanisms of development
  • The molecular landscape of adenocarcinoma and squamous cell carcinoma
Targeted treatments for non-small cell lung cancer
  • Matching mutations to drugs
  • EGF-R targeted treatments (gefitinib, erlotinib, afatinib, dacomitinib & cetuximab)
  • ALK inhibitors (crizotinib, LDK378, alectinib)
  • VEGF-R & multi-kinase inhibitors
  • Novel targets and treatments eg. inhibitors of ROS1, RET, MET, BRAF, HER2, FGFR2
  • Immunotherapy (PD-1 and PDL-1 monoclonal antibodies)
Molecular pathology and targeted treatments for small cell lung cancer
  • The cellular & molecular landscape of small cell lung cancer
  • Targeted treatment approaches for small cell lung cancer
  • Immunotherapy eg. ipilimumab
Case study presentations and discussion